Loading…
Loading…
NEW YORK, April 09, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (“Evome”, the “Company”) (TSXV: EVMT) announced the resignation of Michael Dalsin as Chairman of the Board of Directors. Mr. Chris Heath will remain on the Board and continues to work to capture shareholder value in the various assets held by Evome.
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) is providing an update to shareholders today.
NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company”) (TSXV: EVMT) announces the appointment of Michael Dalsin as Chairman of the Board of Directors. Kenneth Kashkin, MD will take the role of Vice-Chairman. Bill Garbarini will retain his role as COO while stepping off the Board of Directors. Chris Heath was also appointed as a new Director increasing the size of the Board of Directors from five to six.
SHIRLEY, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company”) (TSXV: EVMT) issued a press release on Monday, February 10, 2025 announcing the details of an amendment (the “Amendment”) to the forbearance agreement dated August 4, 2023 between the Company, Biodex Rehab Systems, LLC (“Biodex Rehab”), a wholly owned subsidiary of the Company, and Biodex Medical Systems, Inc. (“Biodex Medical”), a wholly owned subsidiary of Biodex Rehab, and Mirion Technologies (US), Inc. (“Mirion”).
SHIRLEY, N.Y., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company”) (TSXV: EVMT) has announced a significant reduction in its overall debt, strengthening its financial position, as a result of the execution of an amendment (the “Amendment”) to the forbearance agreement dated August 4, 2023 between the Company, Biodex Rehab Systems, LLC (“Biodex Rehab”), a wholly owned subsidiary of the Company, and Biodex Medical Systems, Inc. (“Biodex Medical”), a wholly owned subsidiary of Biodex Rehab, and Mirion Technologies (US), Inc. (“Mirion”).
SHIRLEY, N.Y., Jan. 20, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company”) (TSXV: EVMT) is pleased to announce that the Company's Board of Directors has approved the grant of 1,000,000 restricted stock units (RSUs) to William Garbarini in connection with his appointment as Chief Operating Officer, effective November 22, 2024.
The electric vehicle market appears to be gaining momentum. Outside of the leader in the market, Tesla NASDAQ: TSLA, EV firms are posting new records in sales.
The Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF (PDBC) provides broad-basket commodity exposure. While the fund can stand alone, it can also be used alongside other commodity ETFs.
No recent filings indexed.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for EVMT and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.